Korean J Transplant 2021; 35(4): 208-217
Published online December 31, 2021
© The Korean Society for Transplantation
Harun Ur Rashid , Nura Afza Salma Begum , Tasnuva Sarah Kashem
Department of Nephrology, Kidney Foundation Hospital and Research Institute, Dhaka, Bangladesh
Correspondence to: Harun Ur Rashid
Department of Nephrology, Kidney Foundation Hospital and Research Institute, Plot no. 5/2, Road no. l, section 2, Mirpur, Dhaka 1216, Bangladesh
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Mycobacterium tuberculosis (MTB) infection in solid organ transplant (SOT) recipients remains a major challenge for physicians and surgeons. Active tuberculosis (TB) is associated with increased morbidity and mortality in SOT recipients. MTB usually develops after transplantation in a recipient with latent TB infection (LTBI) before transplantation and may also be transmitted from the donor or acquired from the community. Therefore, screening for LTBI in donors and recipients before transplantation is very important in preventing active disease after transplantation. This review article is based on recently published data, case series, and expert recommendations. We reviewed updated information about the epidemiology, diagnosis, and treatment of latent and active TB before and after transplantation. We also reviewed recent treatments for multidrug-resistant TB.
Keywords: Mycobacterium tuberculosis, Latent tuberculosis infection, Solid organ transplantation, Multidrug-resistant tuberculosis
|View Full Text||PubReader|
|Abstract||Print This Article|
|TOC Alerts||Export to Citation|
|Article as PDF||Open Access|
|Google Scholar||Naver Academic|